Gosselies, Belgium, 14 September 2018, 7 am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces positive final results in the Phase I/IIA delayed-union study of its allogeneic bone cell therapy product ALLOB in 21 patients, supporting the future
PLAINSBORO, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced it has been selected as a primary provider for cellular-based tissue products within Healogics® Inc. new iSupply program. This program is exclusively available to Healogics’ hospital partners and is focused on ensuring hospitals and patients receive the best
WALTHAM, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today announced that its Phase 3 clinical trial of NeoCart did not meet the primary endpoint of a statistically significant improvement in pain and
September 05, 2018 BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer of Keratin Biosciences, Inc., has been appointed as a new independent
MARIETTA, Ga., Aug. 24, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ : MDXG ), a leading developer and marketer of regenerative and therapeutic biologics, today announced that a new study regarding the use of EpiFix® in the treatment of diabetic foot ulcers (DFUs) has been published in the peer-reviewed journal, International Wound Journal. The paper is entitled "A Confirmatory Study on the
CAMBRIDGE, Mass., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the appointment of Jonathan Hopper as Chief Medical Officer. Dr. Hopper formerly served as Senior Medical Director, Orthopedic Clinical Development for Ferring Pharmaceuticals, where he was responsible
BELGRADE, MT, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development and commercialization of regenerative medicine products and medical devices, today announced the appointment of Kathie Lenzen as chief financial officer, effective August 20, 2018. Ms. Lenzen will report to Carl O’Connell, Xtant’s chief executive officer. “Ms.
Lund, Sweden, 18:00 CET, 16 August 2018 - BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that its antibiotic-eluting product CERAMENT G has been approved by Health Canada. CERAMENT G is the first and only CE-marked gentamicin-eluting injectable ceramic bone graft substitute on the market. CERAMENT G sales have been
SAN DIEGO and ERLANGEN, Germany, Aug. 9, 2018 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA) and Siemens Healthineers today announced a strategic partnership focused on technology development, marketing and commercial activities to advance clinical outcomes in minimally invasive spine surgery. NuVasive is an innovation leader in spine health technology, focused on transforming spine surgery with minimally disruptive, predictable and clinically reproducible procedurally-integrated solutions,
Lund, Sweden, 08:00am CET, 2 August 2018 - BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, has signed an agreement with MTF Biologics, the world’s largest tissue bank, to extend and strengthen its US product offering. The agreement will give BONESUPPORT US rights to two forms of bone graft materials comprised
